Inviting all stakeholders in precision medicine to join this landmark summit and collaborate with a panel of esteemed experts to address the economic, policy and operational barriers preventing patient access to life-changing precision medicines.
64.4% of aNSCLC patients in the US may not receive the best treatment for their disease, as highlighted in the globally recognized Journal of Clinical Oncology Precision Oncology publication “The Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer” published in 2022.
In reaction to this critical finding, The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum, composed of 14 leading experts in precision medicine across multiple stakeholders, was established to urgently address the specific economic and operational gaps limiting the advancement of precision medicine and enable every patient to get the treatment they deserve.
At this highly anticipated virtual summit the solutions and recommendations to overcome the challenges obstructing the advancement of precision medicine proposed by the Forum members will be shared and opened for discussion with a live audience.
Join industry peers and avail of this unique opportunity to contribute to a white paper of recommendations for the industry and policy makers and play a critical role in shaping the future of precision medicine.
Why join:
For more information on the summit please contact marketing@diaceutics.com.
Whilst we will endeavour to include all contributions to the summit, it may not be possible to include all contributing content authors.
Chief Precision Medicine Officer, Diaceutics
Senior Vice President of Science Policy, Personalized Medicine Coalition
Life Sciences Senior Advisor and Solutions Architect, Red Nucleus
Director of Global Precision Medicine & Diagnostics, AbbVie
Founder, Clinical Transformation Partners
VP, Head of Global Precision Diagnostics, Novartis & Chair of the Board, Precision Cancer Consortium
Director of Precision Medicine, Point32 Health
Director of University College Dublin Michael Smurfit Graduate Business School
President, Health Collaborations, USA
Chair in Translational Cancer Genomics, Queen's University Belfast
Founder, Diaceutics
Senior Vice President and Chief Genomics Officer, Pathgroup
Vice President of Precision Medicine, BMS
Head of Precision Medicine and Vice President, Merck & Co. Inc
Founder of KRAS Kickers